This Week in Virology
Vincent Racaniello
4 Listeners
All episodes
Best episodes
Top 10 This Week in Virology Episodes
Goodpods has curated a list of the 10 best This Week in Virology episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to This Week in Virology for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite This Week in Virology episode by adding your comments to the episode page.
TWiV 983: One flu vaccine for them all with Scott Hensley
This Week in Virology
02/12/23 • 109 min
Scott returns to TWiV to explain the development of an experimental mRNA vaccine that encodes hemagglutinin antigens against all known influenza A virus subtypes and influenza B virus lineages, and why he is worried about avian H5N1 influenza virus.
Hosts: Vincent Racaniello, Dickson Despommier, and Brianne Barker
Guest: Scott Hensley
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode•Research assistant position at FDA (pdf) •Register for ASV 2023 •MicrobeTV Discord Server •Multivalent influenza mRNA vaccine (Science) •Influenza virus mRNA vaccines circumvent egg adaptation problems (J Virol) •Letters read on TWiV 983 •Timestamps by Jolene. Thanks!
Weekly PicksDickson – Jazz Project: Guitar. Django Reinhardt; Pat Metheny. Signature album: Still Life Talking. Signature song: Last Train Home; Joe Pass (Ella Fitzgerald’s favorite guitar accompanist). Signature album: Virtuoso. Signature song: Round Midnight. Brianne – HHMI Virus Explorer Vincent – Chris Luno
Listener PicksJohn – White-tail deer density and SARS-CoV-2 in white-tail deer Jessica – Classic cases revisited: Oscar the cat and predicting death
Intro music is by Ronald Jenkees Send your virology questions and comments to [email protected]
2 Listeners
TWiV 972: Clinical update with Dr. Daniel Griffin
This Week in Virology
01/07/23 • 42 min
In his weekly clinical update Dr. Griffin discusses the infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave, virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants, antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants, comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans, time to negative PCR conversion among high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated by Sotrovimab or Nirmatrelvir, COVID drug Paxlovid was hailed as a game-changer, what happened?, the Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice, SARS-CoV-2 infection and persistence in the human body and brain at autopsy, long-term cardiovascular outcomes of COVID-19, and how heart-disease risk soars after COVID — even with a mild case.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episode- Infectiousness of breakthrough infections & reinfections during Omicron wave (Nature)
- Virological characteristics of the SARS-CoV-2 XBB variant (bioRxiv)
- Antibody evasion properties of BQ and XBB subvariants (Cell)
- Comparative effectiveness of third doses of mRNA vaccines in US veterans (Nature)
- Time to negative PCR conversion among high-risk patients treated by Sotrovimab or Nirmatrelvir (CMI)
- Paxlovid patient eligbiliity screening checklist (FDA)
- COVID drug Paxlovid was hailed as a game-changer. What happened? (Nature)
- Fc-effector function of COVID-19 convalescent plasma contributes to treatment efficacy (Cell)
- SARS-CoV-2 infection and persistence in the human body and brain at autopsy (Nature)
- Long-term cardiovascular outcomes of COVID-19 (Nature)
- Heart-disease risk soars after COVID (Nature)
- Contribute to our MicrobeTV fundraiser at PWB
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 972
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]
2 Listeners
TWiV 1073: Taming the shrew and barring Epstein-Barr virus
This Week in Virology
12/24/23 • 98 min
TWiV explains a study showing that ost traits shape virome composition and virus transmission in wild bats, rodents, and shrews, and development of a gB nanoparticle vaccine that elicits a protective neutralizing antibody response against Epstein-Barr virus.
Hosts: Vincent Racaniello, Dickson Despommier, and Kathy Spindler
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- MicrobeTV Discord Server
- MicrobeTV store at Cafepress
- Become a member of ASV (asv.org)
- Research assistant position in Rosenfeld Lab CBER/FDA (pdf)
- The New City by Dickson Despommier
- Brett Lindenbach passes (Yale Medicine)
- Virome of small mammals (Cell)
- Epstein-Barr virus nanoparticle vaccine (Cell Host Micr)
- Letters read on TWiV 1073
- Timestamps by Jolene. Thanks!
Dickson – Summary of Global Climate Action at COP 28 and Notable Deaths 2023: Music Kathy – Two APODS Winter solstice, 183 Days in the Sun and the Same color illusion Vincent – The American Academy of Microbiology discusses gain-of-function research of concern (GOFROC) and enhanced potential pandemic pathogens (ePPP)
Listener PicksGregory – Climate Change – A revised prediction – Steven Chu John – Detergent packs are kinda wishy-washy (Technology Connections)
Intro music is by Ronald Jenkees
Send your virology questions and comments to [email protected]
1 Listener
TWiV 1126: Clinical update with Dr. Daniel Griffin
This Week in Virology
06/29/24 • 39 min
In his weekly clinical update, Dr. Griffin discusses RSV vaccination recommendations and revisions to guidelines before reviewing the recent statistics on SARS-CoV-2 infection, data suggesting that individuals with high HLA-DQA2 expression (MHC class II) are better at preventing the onset of a sustained viral infection, how moderate coffee intake can reduce risk of COVID-19 severity but cannabis use resulted in more severe disease but reduced risk of mortality, where to find PEMGARDA, if statin use prevented severe COVID-19, the benefit of administering nirmatrelvir and ritonavir after 5 days, convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if fecal microbiota transplants aid in recovery from COVID-19, and the definition of characteristics and clinical patterns for the diagnosis of long COVID.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- CDC ACIP for RSV (CDC)
- This respiratory virus season everyone age 75 and older receive the RSV vaccine (CDC Newsroom)
- Revised RSV vaccine recommendations (CIDRAP)
- COVID-19 national trend (CDC)
- COVID-19 deaths (CDC)
- Local and systemic response dynamics to SARS-CoV-2 infection (Nature)
- Drink more coffee, reduces risk for SARS-C0V-2 infection (Cell & Bioscience)
- Cannabis, tobacco...smoking in general NOT good for preventing COVID-19 (JAMA Network OPEN)
- Do older versions of the COVID-19 vaccine still provide any protection (JAMA Internal Medicine)
- Where to get pemgarda (Pemgarda)
- CDC Quarantine guidelines (CDC)
- Early phase of SARs-CoV-2 infection (COVID.gov)
- NIH COVID-19 treatment guidelines (NIH)
- Infectious Disease Society guidelines for treatment and management (ID Society)
- Adjuvant statin therapy reduces SARS-CoV-2 mortality (American Journal of Medicine)
- Nirmatrelvir and ritonavir beyond 5 days of symptom onset improved the multiple organ dysfunction in severe COVID-19 patient (BMC Infectious Disease)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (ID Society)
- What do when your heathcare provider is infected with SARS-CoV-2 (CDC)
- Managing healthcare staffing shortages (CDC)
- Steroids,
1 Listener
TWiV 1094: Clinical update with Dr. Daniel Griffin
This Week in Virology
03/09/24 • 53 min
In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of respiratory syncytial virus, influenza and SARS-CoV-2 before discussing revised guidelines for how to treat respiratory viral infection guidelines by the CDC, effectiveness of the new SARS-CoV-2 vaccines and the combination of vaccination and antiviral therapy against the development of disease, continues to dispel the myth of viral rebound, how to pay for paxlovid, the lack of evidence supporting ivermectin as an antiviral drug, when to use steroids and the benefits of convalescent plasma, how COVID-19 affects cognitive function and the effect of long COVID and how healthcare works have difficulty making the proper diagnosis for long COVID even using a questionnaire.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episode- Respiratory disease surveillance (CDC)
- RSV surveillance (CDC)
- RSV national trend (CDC)
- Influenza/flu surveillance (CDC)
- Influenza/flu map (CDC)
- COVID-19 hospital admissions (CDC)
- COVID-19 national trend (CDC)
- COVID-19 wastewater testing (biobot)
- Variant tracker (CDC)
- Variant hospital admissions (CDC)
- What to do when you are sick with a respiratory virus (CDC)
- Basis for respiratory virus guidance (CDC)
- Effectiveness of updated COVID-19 vaccines (MMWR)
- CDC Quarantine guidelines (CDC)
- NIH COVID-19 treatment guidelines (NIH)
- Synergy or additive protection with vaccination and oral antivirals (CID)
- To rebound or to not rebound (MMWR)
- Know your COVID-19 tools (ESMED)
- How to pay for Paxlovid (PAXCESS)
- Molnupiravir safety and efficacy (JMV)
- Still talking about Ivermectin? (Journal of Infection)
- Convalescent plasma recommendation for immunocompromised (IDSociety)
- Steroids,dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- Cognition and memory after COVID-19 (NEJM)
- Loss of IQ after SARS-CoV-2 infection (CIDRAP)
- Really, more evidence for long COVID and impaired cognition (NEJM)
- Memory assessment
1 Listener
TWiV 1088: Clinical update with Dr. Daniel Griffin
This Week in Virology
02/17/24 • 58 min
In his weekly clinical update, Dr. Griffin discusses the use of monoclonal antibody therapy to prevent RSV hospitalization of infants and use of GSK’s RSV vaccine Arexy to prevent severe disease following RSV infection in adults between 50-59 years before he reviews recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, discusses if how the influenza vaccine is manufactured can reprogram the antibody response, cardiovascular consequences of influenza infection, mortality of chikungunya virus infection, if an alternative vaccination schedule impacts the anti-SARS-CoV-2 immune response, dispels the myth that increased mortality correlated with the first vaccine dose, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, how manage long COVID including prevent burnout and compassion fatigue of caring for long COVID patients, whether the CDC or WHO definition of long COVID is beneficial or the use of directed questions, baselines test and listening to the patient tell their story are beneficial in making a long COVID diagnosis.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episode- Nirsevimab immunoprophylaxis to prevent RSV hospitalization (Eurosurveillance.)
- Arexvy given Priority Review in US for the prevention of RSV disease in adults aged 50-59 (GSK)
- Respiratory disease surveillance (CDC)
- RSV surveillance (CDC)
- RSV national trend (CDC)
- Can antibodies be redirected from egg adapted epitopes using recombinant or cell cultured based influenza vaccines (Nat)
- Can influenza infection lead to cardiovascular events (JID)
- Risk of death after chikungunya infection and disease (Lancet)
- Influenza/flu surveillance (CDC)
- Influenza/flu map (CDC)
- COVID-19 hospital admissions (CDC)
- COVID-19 national trend (CDC)
- COVID-19 wastewater testing (biobot)
- Variant tracker (CDC)
- Variant hospital admissions (CDC)
- Alternative intervals between vaccine doses (Nat Comm)
- Early mortality after first vaccination dose (CID)
- CDC Quarantine guidelines (CDC)
- To rebound or to not rebound (MMWR)
- Know your COVID-19 tools (ESMED)
- How to pay for Paxlovid (PAXCESS)
- Molnupiravir
1 Listener
TWiV 1132: Clinical update with Dr. Daniel Griffin
This Week in Virology
07/20/24 • 41 min
In his weekly clinical update, Dr, Daniel Griffin reviews President Biden’s case of COVID, reviews recent statistics on SARS-CoV-2 infection, discusses post-acute sequelae after infection during pregnancy, the use of nirmatrelvir-ritonavir for post-exposure prophylaxis, where to find Pemgarda, effectiveness of combined nirmatrelvir-ritonavir-molnupiravir treatment, effectiveness of Ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19, effectiveness of combined nirmatrelvir-ritonavir-molnupiravir treatment in patients hospitalized with COVID-19, CDC update of Long COVID Basics page, postacute sequelae of SARS-CoV-2 infection in the pre-delta, delta, and omicron eras, Long COVID risk has dropped over time but remains substantial, efficacy of antivirals, corticosteroids, and mAbs as acute COVID treatments in reducing the incidence of long COVID, and the interplay between diet and the gut microbiome: implications for health and disease.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- President Biden has COVID (CNN, USA Today)
- COVID-19 national trend (CDC)
- COVID-19 deaths (CDC)
- Post–acute sequelae of COVID after infection during pregnancy (OB & Gyn)
- Oral nirmatrelvir–ritonavir as postexposure prophylaxis for Covid-19 (NEJM)
- Pemgarda infusion center locator (Pemgarda)
- Unable to access pemgarda, gotta call Daniel (microbeTV)
- CDC Quarantine guidelines (CDC)
- Early phase of SARs-CoV-2 infection (COVID.gov)
- NIH COVID-19 treatment guidelines (NIH)
- Infectious Disease Society guidelines for treatment and management (ID Society)
- Drug interaction checker (University of Liverpool)
- Combined treatment of COVID reduces molnupiravir-induced mutagenicity (J Inf Dis)
- Effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19 (Inf Dis Therapy)
- Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy (Lancet)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (ID Society)
- Isolation guidance (CDC)
- Managing healthcare staffing shortages (CDC)
- Steroids, dexamethasone at the right time (OFID)
1 Listener
TWiV 1124: Clinical update with Dr. Daniel Griffin
This Week in Virology
06/22/24 • 40 min
In his weekly clinical update, Dr. Griffin reviews the recent statistics on SARS-CoV-2 infection, before discussing methods for sterilizing filtering facepieces, an update to the fall COVID boosters, the emergency use application of a pre-exposure prophylactic and where to find it and drug interaction database, convalescent plasma, the effectiveness of the monoclonal antibody sotrovimab against Omicron variants, what to do when healthcare workers succumb to SARS-CoV-2 infection, the need for better nursing resources, how survivors of COVID-19-associated ARDS exhibited sustained elevation in endothelial dysfunction biomarkers, correlating with the severity of impaired gas exchange, reactivation of latent CMV as a consequence of a SARS-CoV-2 infection, identification of variables that might impact or predict a person’s time to recovery from an acute SARS-CoV-2 infection and if COVID-19 patients really have olfactory dysfunction more often than normally smelling individuals.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- COVID-19 national trend (CDC)
- COVID-19 deaths (CDC)
- Comparison of methods for sterilizing filtering facepiece respirators (American Journal of Infection Control)
- Booster update already! KP.2 of JN.1-lineage (FDA)
- EUA for pemgarda (FDA)
- Where to get pemgarda (Pemgarda)
- CDC Quarantine guidelines (CDC)
- Early phase of SARs-CoV-2 infection (COVID.gov)
- NIH COVID-19 treatment guidelines (NIH)
- Infectious Disease Society guidelines for treatment and management (ID Society)
- Drug interaction checker (University of Liverpool)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (ID Society)
- Revisiting monoclonal antibody therapy, sotrovimab for treatment during Omicron BA.2 and BA.5 (Infection)
- What do when your healthcare provider is infected with SARS-CoV-2 (CDC)
- Managing healthcare staffing shortages (CDC)
- Steroids,dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- Hospital nurse staffing variation & COVID-19 (International Journal of Nursing Studies)
- Endothelial dysfunction and persistent inflammation severe post-COVID-19 (BMC Medicine)
- Prevalence and risk for
1 Listener
TWiV 1104: Clinical update with Dr. Daniel Griffin
This Week in Virology
04/13/24 • 46 min
In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of measles before addressing results of Pfizer’s phase 3 RSV vaccine clinical trial for adults under 60, RSV, influenza and SARS-CoV-2 circulation, differences between rural and urban communities dealing with SARS-CoV-2 infections, the latest statistics on influenza and COVID-19 circulation, restates the guidelines for spring administration of COVID vaccines boosters, discusses the emergency use application of a pre-exposure prophylactic. revised guidelines for how to treat respiratory viral infection guidelines by the CDC, continues to dispel the myth of viral rebound, revised guidelines SARS-CoV-2 treatment and how to treat respiratory viral infections, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, how long COVID affects the brain and associates with an increase in allergic incidents as well as if post SARS-CoV-2 infected patients are unable to exercise or have functional limitations. For more information about this body of work, listen to TWiV 1088.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Measles tracking (CDC)
- Measles just this year (MMWR)
- ABRYSVO phase 3 results (Pfizer)
- RSV surveillance (CDC)
- Influenza/flu surveillance (CDC)
- Provisional deaths due to COVID-19 (CDC)
- COVID-19 national trend (CDC)
- COVID-19 wastewater testing (biobot)
- Variant tracker (CDC)
- Rural-urban differences in COVID-19 mortality and hospitalizations (OFID)
- Spring COVID-19 booster recommendations (CIDRAP)
- Older adult spring booster available (CDC)
- Advisory committee for immunization practices spring 2024 COVID-19 boosters (CDC)
- EUA for pemgarda (FDA)
- CDC Quarantine guidelines (CDC)
- NIH COVID-19 treatment guidelines (NIH)
- Nirmatrelvir for vaccinated or unvaccinated COVID-19 patients (NEJM)
- Assessment for clinical usefulness (NEJM)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (IDSociety)
- Updated respiratory virus guidances (CDC)
- What do when your heathcare provider is infected with SARS-CoV-2 (CDC)
- Managing healthcare staffing shortages (CDC)
- Steroids,
1 Listener
TWiV 1072: Clinical update with Dr. Daniel Griffin
This Week in Virology
12/23/23 • 38 min
In his weekly clinical update Dr. Griffin discusses the annual economic burden of respiratory syncytial virus in adults in the US, recombinant or standard-dose influenza vaccine in adults under 65 years of age, maternal vaccine effectiveness against influenza-associated hospitalizations and emergency department visits in iInfants, influenza positive tests reported to CDC by US clinical laboratories, update on COVID-19, risk of severe maternal morbidity associated with SARS-CoV-2 infection during pregnancy, COVID-19 rapid antigen tests with self-collected vs health care worker–collected nasal and throat swab specimens, optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation, long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study, and risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- RSV economic burden, US (J Inf Dis)
- Recombinant or standard dose influenza vaccine (NEJM)
- Maternal vaccine effectiveness against influenza in Infants (JAMA Ped)
- Weekly influenza surveillance report (MMWR)
- COVID data tracker (hospital admissions, national trend)
- Risk of severe maternal morbidity associated with SARS-CoV-2 infection (J Inf Dis)
- COVID-19 rapid antigen tests with nasal and throat swab specimens (JAMA Net Open)
- Optimal timing of nirmatrelvir/ritonavir (Nat Comm)
- Long-term outcomes following hospital admission for COVID-19 vs influenza (Lancet)
- Contribute to our MicrobeTV fundraiser at PWB
- Letters read on TWiV 1072
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
1 Listener
Show more best episodes
Show more best episodes
FAQ
How many episodes does This Week in Virology have?
This Week in Virology currently has 1193 episodes available.
What topics does This Week in Virology cover?
The podcast is about Life Sciences, Microbiology, Natural Sciences, Podcast, Podcasts, Science, Disease and Virus.
What is the most popular episode on This Week in Virology?
The episode title 'TWiV 972: Clinical update with Dr. Daniel Griffin' is the most popular.
What is the average episode length on This Week in Virology?
The average episode length on This Week in Virology is 88 minutes.
How often are episodes of This Week in Virology released?
Episodes of This Week in Virology are typically released every 6 days.
When was the first episode of This Week in Virology?
The first episode of This Week in Virology was released on Sep 24, 2008.
Show more FAQ
Show more FAQ